Most IV HTN Meds Ordered for Patients With SBP <180 mm Hg

This article originally appeared here.
Share this content:
Most IV HTN Meds Ordered for Patients With SBP &#60;180 mm Hg
Most IV HTN Meds Ordered for Patients With SBP <180 mm Hg

THURSDAY, Nov. 19, 2015 (HealthDay News) -- Intravenous (IV) antihypertensives are often ordered and administered for patients with asymptomatic uncontrolled blood pressure (BP) levels that are not associated with immediate cardiovascular risk, according to a study published online Nov. 12 in the Journal of Hospital Medicine.

Melissa Lipari, Pharm.D., from Wayne State University in Detroit, and colleagues examined the frequency of prescribing and administering episodic IV antihypertensives and outcome in non-critically ill, hospitalized patients. Data were included for 246 patients with an episodic IV antihypertensive order.

Of the patients with an episodic IV antihypertensive order, 172 received 458 doses, with 48 percent receiving a single dose. The researchers found that more than 98 and 84.5 percent of episodic IV antihypertensive doses were administrated for systolic blood pressure (SBP) of <200 mm Hg and <180 mm Hg, respectively. For patients receiving IV hydralazine and labetalol, there was a statistically significant decrease in average SBP and diastolic BP within six hours of administration. The oral inpatient medication regimen was adjusted in 52 percent of patients after administration of IV antihypertensives; compared to patients with no change to their oral regimens, these patients had a greater SBP reduction from admission to discharge.

"IV antihypertensive drugs are ordered and administered in patients with asymptomatic, uncontrolled BP for levels unassociated with substantive immediate cardiovascular risk, which may cause adverse effects," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »